Recent large-scale studies support that sodium-glucose cotransporter-2 (SGLT2) inhibitors lower the risks for kidney stones better than other drugs for ... for a full list of authors’ disclosures.

they want more data and may not trust SGLT2 inhibitors yet. Other HCPs want cardiologists to be leaders in this space, feeling that they should use these drugs in practice and share their ...

SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...

To explore this further, researchers set out to compare the effects of SGLT-2 inhibitors on risk of recurrent kidney stones ...

Urinary glucose excretion (g/24 h):/DP100 mg: 69.9/DP20 mg: 70.1/DP5 mg: 36.6 No serious adverse drug reactions or ... Main action of SGLT2 inhibitors is the induction of glucosuria and osmotic ...

The analysis of sodium glucose cotransporter 2 (SGLT-2) inhibitor drugs in patients on a national Danish registry found they were associated with a 25% lower risk of all-cause mortality, ‘supporting ...

Link Win SGLT2 inhibitors receive FDA fast track designation to reduce risk of death in patients with chronic kidney disease How to prevent fecal-oral transmis ...